Adcendo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adcendo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adcendo Today - Breaking & Trending Today

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of. ....

San Diego , United States , Landskapet Birkaland , Southwest Finland , Lars Engelholm , Dominik Mumberg , Cancer Research , Finsen Laboratory , Aurexel Life Sciences , Novo Holdings , Clinical Research Immunology , University Of Copenhagen , Cancer Invasion Section Of The Finsen Laboratory , American Association For Cancer Research , American Association , Annual Meeting , Chief Scientific Officer , Associate Professor , Cancer Invasion Section , Life Sciences , Ysios Capital , Pontifax Venture Capital ,

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of. ....

John Zhu , Michael Pehl , Novo Holdings , Duality Biologics , Duality Immune Toxin Antibody Conjugates , Option License Agreement , Chief Executive Officer , Ysios Capital , Pontifax Venture Capital ,

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of. ....

Michael Pehl , Novo Holdings , Pontifax Venture Capital , Ysios Capital , Gilde Healthcare , Ohad Hammer , Adcendo Board , Development Candidate Nomination , Chief Executive Officer , Candidate Nomination , Board Director ,

Adcendo funding boosts antibody-drug conjugates development

Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP - News - PharmaTimes ....

Michael Pehl , Novo Holdings , Pontifax Venture Capital , Ysios Capital , Gilde Healthcare , Ohad Hammer ,

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality's DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC programAgreement based on synergies between Adcendo and Duality in ....

John Zhu , Kostenloser Wertpapierhandel , Michael Pehl , Novo Holdings , Duality Immune Toxin Antibody Conjugates , Duality Biologics , Chief Executive Officer , Ysios Capital , Duality Immune Modulating Antibody Conjugates ,